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PURPOSE. To study the relationship between baseline spherical
equivalents (SphE) of refraction and prevalent as well as inci-
dent age-related maculopathy (pARM and iARM, respectively).
METHODS. The study was performed as part of the Rotterdam
Study, a population-based, prospective cohort study. The SphE
(in diopters), measured with autorefraction and subjective op-
timization, was recorded in 6209 subjects aged 55 years or
more. Aphakic or pseudophakic eyes at baseline were ex-
cluded. Stereoscopic transparencies of the macular region
were graded according to the International Classification and
Grading System. ARM was defined as large soft drusen with
pigmentary changes, or indistinct drusen, or atrophic or neo-
vascular age-related macular degeneration (AMD). For the prev-
alence analyses, ARM was classified into no, p(early)ARM, or
pAMD, and in each subject the eye with the most advanced
ARM and the corresponding refraction was selected. After a
mean 5.2 years of follow-up, 4935 subjects had complete data
for these incidence analyses. In each subject, the eye with
iARM was selected.
RESULTS. The age- and gender-adjusted odds ratio (OR) of pARM
(n  536) for every diopter of progress toward hyperopia was
1.09 (95% confidence interval [CI]1.04–1.13). For p(early)ARM
(n 440) the OR was 1.09 (1.04–1.14) and for pAMD (n 96)
the OR was 1.09 (1.00–1.19). Baseline refraction was signifi-
cantly associated with increased risk of iARM (n  497). For
each diopter of progress toward hyperopia the OR was 1.05
(95% CI 1.01–1.10). Additional adjustments for smoking, ath-
erosclerosis, and blood pressure did not alter the relationship.
CONCLUSIONS. These population-based incidence data confirm
results from prevalence and case-control studies that there is an
association between hyperopia and ARM. (Invest Ophthalmol
Vis Sci. 2003;44:3778–3782) DOI:10.1167/iovs.03-0120
Age-related maculopathy (ARM) may be characterized by anaccumulation of abnormal extracellular deposits (called
drusen) in the vicinity of Bruch’s membrane,1 with or without
pigmentary changes at the level of the retinal pigment epithe-
lium (RPE). Its end stage, also called age-related macular de-
generation (AMD), is the major cause of incurable visual im-
pairment in the Western world. Over the years, it has been
proposed that these drusen are a manifestation of dysfunction
and degeneration of the RPE and retina.1 These age-related
changes may also be a manifestation of restricted exchange of
nutrients and other metabolic products between the neural
retina across Bruch’s membrane toward the choroid.
At the moment, there is limited long-term effective treat-
ment for AMD.2–4 In a small number of subjects with neovas-
cular AMD, laser photocoagulation and photodynamic therapy
can be successfully used in delaying visual loss. Recently, the
AREDS trial5 showed a protective effect of high-dose supple-
mentation with antioxidant vitamins and zinc in a subset of
ARM cases. In view of preventive measures, better knowledge
of pathophysiology and detection of early stages6 is important.
Different studies7 have looked at various risk factors in-
volved in AMD, such as smoking, atherosclerosis, and genetic
factors. Similarly, it has been hypothesized that ocular factors,
such as cataract (extraction), iris color, and refractive errors
may also be involved in the development of this disease.8,9 The
association between hyperopia and AMD was first described by
Maltzman et al.10 in 1979 in a case–control setting. After that,
a few other case–control11–14 studies on this topic showed
conflicting results. One report of a population-based cross-
sectional study15 mentioned a weak association between hy-
peropia and early ARM (per diopter of progress toward hyper-
opia: OR: 1.1; 95% CI: 1.0–1.2). More recently, a population-
based follow-up study16 showed no relationship between
refractive error and 10-year incidence of early ARM (hyperopia
1.0 D versus emmetropia: relative risk [RR]: 0.9: 95% CI:
0.7–1.1) and AMD (RR: 1.2; 95% CI: 0.6–2.3).
Because the nature of the association between refraction
and ARM is still unclear and may provide insight into the
pathogenesis of this disease, we examined the association
between baseline refraction and prevalent (pARM) as well as
incident ARM (iARM) in a population-based setting.
METHODS AND MATERIALS
Population
Information on the identification and description of the baseline study
population has appeared in previous reports.17 Briefly, the Rotterdam
Study is a population-based prospective cohort study of the frequency
and determinants of common cardiovascular, locomotor, neurologic,
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and ophthalmologic diseases. The eligible population (n  10,275)
consisted of all inhabitants aged 55 years or more in a suburb of
Rotterdam, the Netherlands. Of these, 7983 (78%) agreed to participate
in the study. Because the ophthalmic phase of the study became
operational after the screening of participants had started, a smaller
portion (n  6780) underwent ophthalmic examination. The study
was conducted according to the tenets of the Declaration of Helsinki,
and the medical ethics committee of the Erasmus Medical Center
approved the study protocol. Written informed consent was obtained
from all participants. Baseline interviews and examinations were per-
formed from 1990 to mid-1993, followed by a first follow-up examina-
tion from 1993 to 1994. A second follow-up screening took place from
mid-1997 to the end of 1999.
Diagnosis of Age-Related Maculopathy
A detailed description of the diagnostic procedures has been presented
elsewhere.18 Participants underwent a full eye examination, including
stereo 35° fundus photography (Topcon TRV-50VT fundus camera;
Topcon Optical Company, Tokyo, Japan) centered on field 2 (the
fovea) after pharmacologic mydriasis. The resultant transparencies
were graded with 12.5 magnification according to the International
Classification and Grading System for ARM and AMD.19 In this system,
all ARM fundus signs within a standard circular area (diameter 6000
m) around the fovea are recorded. Two graders, trained according to
the Wisconsin ARM grading system and each having 8 years experi-
ence, first graded the follow-up transparencies after which these were
compared with those taken at baseline. The grading procedures and
definitions, as well as the graders, were identical at baseline and at
follow-up. Consensus sessions and between-grader comparisons were
performed regularly. Weighted  statistics were 0.72 for soft distinct
drusen, 0.80 for hyperpigmentation, and 0.58 for hypopigmentation.
ARM was defined as the presence of large (63 m), soft, distinct
drusen with pigmentary irregularities, indistinct (125 m) or reticu-
lar drusen, or atrophic or neovascular AMD. Atrophic AMD was de-
fined as any sharply demarcated round or oval area of apparent ab-
sence of RPE, larger than 175 m, irrespective of distance from the
foveola but within the grid, with visible choroidal vessels and no
neovascular AMD. Neovascular AMD was defined as the presence of a
serous or hemorrhagic neuroretinal or RPE detachment and/or a sub-
retinal neovascular membrane and/or a subretinal hemorrhage and/or
a periretinal fibrous scar. Lesions that were considered to be the result
of generalized disease, such as diabetic retinopathy, chorioretinitis,
high myopia, trauma, congenital diseases, or photocoagulation for
reasons other than neovascular AMD, were excluded from ARM clas-
sification.
Refraction
Refraction of each eye was taken as the mean of three measurements
per eye with an autorefractometer (Topcon RM-2000; Topcon Corp.,
Tokyo, Japan) followed by subjective optimization. The medical doc-
tors performing these measurements were trained by ophthalmolo-
gists, and quality control sessions were conducted routinely. In 2.5% of
all subjects (1.9% of both eyes and 0.6% one eye) these autorefractom-
eter measurements could not be obtained, mostly because of lens
opacities or physiological miosis. The amount of correction of the
subjects’ spectacles (if present) was measured with a lensometer (Top-
con CL-1000; Topcon Corp.). Subjects with no autorefraction data and
who did not have glasses were excluded from our analyses. For all
analyses, the spherical equivalents (SphE) were calculated and ex-
pressed in diopters.
Study Sample
Of the 6780 participants in the ophthalmic part of the baseline study,
6477 (95.5%) underwent fundus photography, and 6418 (94.7%) had
gradable fundus transparencies in at least one eye. Prevalent ARM was
diagnosed in 582 (9.1%) subjects, including 106 with AMD. This re-
sulted in a cohort of 5836 subjects at risk who were free of ARM (i.e.,
subjects with no drusen, only hard drusen or soft drusen, or pigmen-
tary abnormalities only). Of this cohort, 283 (4.8%) subjects died
before the first follow-up examination, and another 789 (13.5%) sub-
jects died before the second follow-up. Of those alive at the first
screening (n  5553), 46 subjects were lost to follow-up, 905 refused
to participate, and 13 had ungradable photographs. Of those alive at
the second follow-up (n  4764), 15 subjects were lost to follow-up,
1267 refused to participate, and 47 had ungradable photographs. In
total, 4822 subjects (83% of those at risk) participated in at least one
follow-up examination.
Of the 6418 (94.7%) subjects at baseline, 6209 (91.6%) were in-
cluded in the cross-sectional analysis, after excluding those with miss-
ing data on refraction and those who had had a cataract extraction in
both eyes at baseline. In these subjects, prevalent early ARM (p(earl-
y)ARM) was diagnosed in 440 and prevalent AMD (pAMD) in 96 (total
prevalent ARM (pARM) n  536). P(early)ARM was defined as pARM
excluding pAMD.
In the follow-up analyses of incident ARM (iARM), all persons free
of ARM at baseline and who participated at least in one follow-up
examination were included (n 4822). Furthermore, if the second eye
of a pARM case was free of ARM, that eye was also included in this
analysis, because we were looking at an eye-specific risk factor. Hence,
4935 (72.8%) subjects of the 6209 participants at baseline on whom we
had complete data were included in the follow-up analyses, resulting in
497 cases of iARM. Incidence of ARM was defined as absence of ARM
in an eye at baseline and presence of ARM in the same eye at follow-up.
The mean follow-up time for the first examination was 2 years and for
the second examination 6.5 years. The overall mean follow-up time
was 5.2 years.
Statistical Analyses
Analyses were started by taking the SphE in diopters as a continuous
variable. Next, cutoff points were taken to define (advanced) myopia
TABLE 1. Baseline Characteristics and Prevalence of Early ARM and AMD per Stratum of Refraction
Advanced Myopia* Myopia† Emmetropia‡ Hyperopia§ Advanced Hyperopia
Number 443 770 966 3180 850
Mean age (y) 67.4 68.0 67.2 68.6 71.9
Gender (% female) 53.3 56.1 58.9 59.6 63.1
Mean SphE (D) 5.5 1.4 0.0 1.6 4.3
p(early)ARM (n, %) 16 (3.6) 57 (7.4) 50 (5.2) 227 (7.1) 90 (10.6)
pAMD (n, %) 4 (0.9) 10 (1.3) 16 (1.7) 43 (1.4) 23 (2.7)
N  6209.
* Advanced myopia: SphE  3.0 D.
† Myopia: 3.0 D  SphE  0.5 D.
‡ Emmetropia: 0.5 D  SphE  0.5 D.
§ Hyperopia: 0.5 D  SphE  3.0 D.
 Advanced hyperopia: SphE  3.0 D.
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and (advanced) hyperopia. In the legend of Table 1, the cutoff points
are further specified. For categorized analyses, emmetropic eyes were
used as the reference group.
For cross-sectional analyses in each subject, the eyes were classified
into no ARM, p(early)ARM, or pAMD. Subsequently, the eye with most
advanced ARM was chosen, and the corresponding refraction of the
same eye was included in the analyses. If both eyes had no ARM or the
same pARM diagnosis, the right eye was chosen. However, if one eye
was aphakic or pseudophakic and the other phakic, the latter was
included. Subjects with bilateral cataract extraction at baseline were
excluded from the analyses. The association between the SphE (in a
continuous and a categorized way) and pARM was analyzed using
logistic regression models adjusted for age and gender. To explore this
relationship further, we performed the analyses for p(early)ARM and
pAMD separately.
For the incidence analyses, the eye that had iARM was selected, and
the corresponding refraction of that same eye at baseline was used. In
case iARM developed in both eyes, the right eye was chosen. Again,
logistic regression modeling was performed to establish the relation-
ship of baseline SphE with iARM correcting for age, gender, and
follow-up time. Follow-up time was calculated using the dates on
which the baseline and follow-up photographs were made. Because of
the low number of incident AMD (iAMD) cases, the analyses were not
performed separately for incident early ARM (i(early)ARM) and iAMD.
In multivariable models, we further adjusted for smoking, atheroscle-
rosis, and blood pressure at baseline.
RESULTS
Table 1 shows some general characteristics and the prevalence
of ARM in our study population that was used for the cross-
sectional analyses. In Figure 1 the distribution of refraction at
baseline is presented (mean SphE  0.83  2.6 D; [SD]).
Analyses with SphE as a continuous variable showed that every
diopter of progress toward hyperopia gave an age- and gender-
adjusted odds ratio (OR) of 1.09 (95% confidence interval
[CI]: 1.04–1.13) for pARM (Table 2). Furthermore, when
p(early)ARM and pAMD were studied separately, the risk esti-
mates were the same for both. Every diopter of progress
toward hyperopia gave a significantly increased odds ratio for
both p(early)ARM (OR: 1.09; 95% CI: 1.04–1.14) and pAMD
(OR: 1.09; 95% CI: 1.00–1.19). Repeating the analyses with
categorized SphEs (as defined in the legend to Table 1) showed
that the risk of pARM was 46% higher in eyes with advanced
hyperopia than in emmetropic eyes. In the categorized an-
alyses, the association between advanced hyperopia and
p(early)ARM (OR: 1.62; 95% CI: 1.12–2.34) was still statistically
significant, whereas the association disappeared for pAMD
(OR: 1.14; 95% CI: 0.57–2.24). After additional adjustments for
smoking, atherosclerosis and blood pressure, a statistically sig-
nificant risk of pARM (OR: 1.07; 95% CI: 1.03–1.12) was found
for every diopter of progress toward hyperopia.
There were 497 subjects with iARM, and Table 3 shows the
incidence of ARM stratified according to the refractive status of
the eye. The same, but attenuated, results were found for the
association between baseline refraction and iARM (Table 4).
After adjusting for age, gender, and follow-up time, every
diopter of progress toward hyperopia increased the risk of
iARM with 5% (OR: 1.05; 95% CI: 1.01–1.10). In the catego-
rized analyses the risk estimates were not statistically signifi-
cant, though there seemed to be a trend. After additional
adjustments for smoking, atherosclerosis, and blood pressure,
the risk of iARM (OR: 1.04; 95% CI: 1.00–1.09) for every
diopter of progress toward hyperopia remained statistically
significant.
DISCUSSION
Both the cross-sectional, and to a lesser extent, the follow-up
results show that hyperopia is positively associated with ARM.
For the proper interpretation of these findings we have to keep
in mind several methodological aspects.
Subjects included in the present analyses differed from
those excluded at baseline. These excluded subjects were not
only those who did not participate in this study in the first
place, but also those who were excluded because of missing
data, ungradable photographs at baseline, or bilateral cataract
extraction at baseline. Subjects who had had a bilateral cataract
extraction were excluded, because we did not know the true
refractive value of their natural lens and because of a potential
FIGURE 1. Distribution of refraction at baseline (n  6209).
TABLE 2. Odds Ratios of Prevalent ARM According to Spherical Equivalents of Refraction
SphE
(Continuous)*
OR (95% CI)
Advanced
Myopia
vs.
Emmetropia
OR (95% CI)
Myopia vs.
Emmetropia
OR (95% CI)
Hyperopia vs.
Emmetropia
OR (95% CI)
Advanced Hyperopia vs.
Emmetropia
OR (95% CI)
pARM (n  536) 1.09 (1.04–1.13) 0.64 (0.38–1.09) 1.21 (0.83–1.74) 1.18 (0.89–1.58) 1.46 (1.05–2.04)
p(early)ARM (n  440) 1.09 (1.04–1.14) 0.67 (0.37–1.20) 1.37 (0.92–2.05) 1.32 (0.96–1.82) 1.62 (1.12–2.34)
pAMD (n  96) 1.09 (1.00–1.19) 0.61 (0.20–1.89) 0.71 (0.31–1.64) 0.87 (0.47–1.59) 1.14 (0.57–2.24)
Data adjusted for age and gender. For definition of conditions, see Table 1.
* Range, 18.75 D to 15.13 D; OR for every diopter of progress toward hyperopia.
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relationship between cataract extraction and ARM.9 To avoid
misclassification of refractive status, these subjects had to be
excluded. The excluded subjects at baseline were on average
older and more often institutionalized. Exclusion of this older
cohort, that probably contained relatively more cases of ARM
due to the older age distribution, may cause an imprecision in
the estimate of the associations, leading to wider confidence
intervals. However, we do not think that the point estimates
(OR) were affected due to selection bias by this exclusion.
Although it is possible that having ARM causes nonparticipa-
tion, it is in our opinion unlikely that this nonparticipation was
influenced by the refractive status.
This issue becomes even more important regarding the
iARM analyses. As in any follow-up cohort, ours also showed
that a relatively healthier population visited the research center
during the follow-up examinations, which again produced an
imprecision of an underlying association, but probably not a
selection bias.
Taking SphE as a continuous variable assumes that there is
no biological difference between myopia and hyperopia. Be-
cause this assumption is not based on any empiric evidence
and because there are many different ocular disorders associ-
ated with myopia versus hyperopia, we preferred to define
myopia and hyperopia also using cutoff values, with a group of
emmetropic eyes as reference category. After doing so, we can
still conclude that the relationship between ARM and hyper-
opia seems to be unaltered. Furthermore, the cutoff SphEs
were chosen after considering the distribution of refraction in
this population. When the analyses were repeated with other
cutoffs, we saw similar results (data not shown). We decided to
take the presented cutoff values mainly to secure large enough
numbers in all categories.
Our cross-sectional data have limitations when it comes to
causal relationships. However, because nearly all previous
studies have used cross-sectional data for this association, we
also analyzed our p(early)ARM and pAMD cases to compare
our results with those in other studies. One report from a
population-based cross-sectional study mentioned a weak asso-
ciation between hyperopia and only early ARM15 (per diopter
of progress toward hyperopia; OR: 1.1, 95% CI: 1.0–1.2). The
case–control AREDS study13 showed an association between
hyperopia and large drusen as well as with neovascular and
atrophic AMD. However, recently a population-based fol-
low-up study16 showed no relationship between refractive
status and the 10-year incidence of ARM. On the basis of our
cross-sectional analyses, we can confirm that there seems to be
a relationship between SphE and p(early)ARM and pAMD.
Furthermore, our results from the follow-up analyses support
the hypothesis that there may be a causal relationship. In our
attempt to fully explore the relationship between refraction
and i(early)ARM as well as iAMD separately we were, however,
limited by the small number of iAMD cases.
Also, diagnostic procedures must be considered. Drusen in
myopic fundi may be more difficult to assess because the
usually fairer RPE and choroidal pigmentation results in a
blonder fundus and less contrast. Another diagnostic pitfall
may be that during the grading of the fundus transparencies no
Littmann’s correction was used for the variation in magnifica-
tion caused by the refractive state of that eye. A photograph of
a hyperopic eye will lead to a larger magnification due to the
hyperopia compared with a myopic (or even an emmetropic)
eye. This could have introduced a misclassification into our
grading of drusen and may play a role to a certain extent in the
cross-sectional analyses. In the follow-up analyses, however,
the incident cases were defined as a change in ARM stage and
the absolute dimensions of the drusen per se were not impor-
tant. Thus, here the magnification should pose fewer prob-
lems. There could finally be a tendency to classify a “neovas-
cular AMD” eye in a myopic fundus with a few or no drusen as
a myopic disciform reaction or Fuch’s spot instead of neovas-
cular AMD. This could (partly) account for the association we
found between hyperopia and neovascular pAMD (per diopter
of progress toward hyperopia: OR: 1.21, 95% CI: 1.09–1.36).
Additional adjustments for other known risk factors such as
smoking, blood pressure, and atherosclerosis did not signifi-
cantly alter this relationship, showing that refraction has an
additional effect on the development of ARM. At baseline
13.4% of participants used any type of micronutrient supple-
ments, but we did not have any information on the exact dose,
type, and duration of use. Moreover, we are unaware of an
association between micronutrient use and refraction, there-
fore we did not adjust for this use.
The pathophysiological mechanism by which hyperopia
may lead to ARM still remains to be elucidated. We think that
of the three components determining the refraction of an eye,
corneal curvature, lens power, and axial length, the latter one
is most likely to play a role in the pathogenesis of ARM. In
general, hyperopic eyes are smaller and have thicker and more
rigid and compact sclerae.20 This generalized stiffness of the
sclera may cause an increase in resistance of the choroidal
venous outflow21,22 with throttling of the vorticose veins, and
a thicker choroid.23,24 Both histologic and in vivo studies with
laser Doppler flow measurements have shown an increased
choroidal resistance in AMD-cases compared with gender- and
TABLE 3. Incidence of ARM per Stratum of Refraction in Absolute Numbers
Advanced Myopia Myopia Emmetropia Hyperopia Advanced Hyperopia
Number 372 622 778 2540 623
iARM* (n, %) 26 (7.0) 48 (7.7) 73 (9.4) 270 (10.6) 80 (12.8)
For definition of conditions, see Table 1. n  4935.
* Due to the low number of iAMD cases, they are not presented separately.
TABLE 4. Odds Ratios of Early Incident ARM, According to Spherical Equivalents of Refraction
SphE
(Continuous)*
OR (95% CI)
Advanced Myopia
vs. Emmetropia
OR (95% CI)
Myopia vs.
Emmetropia
OR (95% CI)
Hyperopia vs.
Emmetropia
OR (95% CI)
Advanced Hyperopia
vs. Emmetropia
OR (95% CI)
iARM (n  497) 1.05 (1.01–1.10) 0.69 (0.43–1.11) 0.79 (0.53–1.16) 1.09 (0.82–1.43) 1.20 (0.85–1.69)
Data adjusted for age, gender and follow-up time. For definition of conditions, see Table 1.
* Range, 18.75 D to 9.63 D; OR for every diopter of progress toward hyperopia.
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age-matched controls.25 We speculate that decreased flow pre-
vents easy exchange of nutrients and metabolic products
across the RPE and results in drusen formation and thickening
of Bruch’s membrane. However, the exact role of these vascu-
lar abnormalities26 in the pathogenesis of ARM remains un-
clear.
Other speculations that may explain the observed associa-
tion with hyperopia are that poorer cooling of the retina by an
impaired choroidal blood flow may lead to a higher suscepti-
bility to oxidative stress. Also the thicker retina in hyperopic
versus myopic eyes may have a higher need for oxygen and
nutrients. Furthermore, it is uncertain whether the photore-
ceptor density per square millimeter of the fovea or per RPE
cell is different in hyperopia.
Although the magnitude of the risk estimates associated
with refraction is lower than that of the major well-known risk
factors such as age and smoking,7 the risk of 5% to 9% per
diopter of progress toward hyperopia is still a considerable
increase. In view of these findings, special attention may have
to be given to older persons with hyperopia (e.g., over 70 years
with hyperopia 3.0 diopter) to offer them in the presence of
ARM a potential benefit from micronutrient supplementation.
In conclusion, this large population-based cohort study
showed also in a prospective way that hyperopia is a risk factor
for ARM.
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